Physiotherapy management of a rare variant of Guillain Barre Syndrome, acute motor and sensory axonal neuropathy (AMSAN) along with COVID-19 in a 35-year-old male –a case report

Abstract

Introduction: COVID-19 emerged as a novel pandemic with serious illness. Acute motor and sensory axonal neuropathy, a Guillain-Barré syndrome variant also results in ventilator support, and bed-ridden state. Presence of COVID-19 along with GBS will cause serious complications if left untreated.
 Objective: To report the effect of physiotherapy in acute motor and sensory axonal neuropathy along with COVID-19 in Intensive care unit.
 Case description: A 35-year-old-male with AMSAN, alcoholic hepatitis, and hyponatremia, came with paraparesis, ventilated due to poor oxygen saturation, diagnosed to have COVID-19, reduced muscle power in right wrist extensors, hand grip and diaphragm.
 Method: 30 minutes physiotherapy session, thrice a day for a period of 4 weeks. The vital signs were taken as a primary outcome measure. Medical Research Council muscle power grading and Hughes functional grading scale were taken as secondary outcomes. All the outcome measures were assessed for 4 weeks.
 Results: The 4 weeks of physiotherapy program show significant improvements on health status, muscle power, and functional status of an AMSAN patient with COVID 19.
 Conclusion: From the results, it can be concluded that physiotherapy will be beneficial in AMSAN patients with COVID-19 in Intensive care units and further studies have to declare evidence-based practice.
 Keywords: Acute motor-sensory axonal neuropathy; Intensive care unit; COVID-19; Gullian Barre syndrome.

Rehabilitation of a 51-Year-Old Patient With Miller Fisher Syndrome: A Case Report

“…The severity and duration of symptoms are brought into focus, making a conventional treatment strategy more challenging to follow, and calls for additional study into how innovative therapies affect healing [15]. The functional state was evaluated using the Hughes disability scale, whereas the muscle power was evaluated using the Medical Research Council (MRC) grades [16]. Presently, there hasn't been any epidemiological research that explicitly evaluates the occurrence and rate of Miller Fisher syndrome [17].…”

Editorial I: So, who wins? It is still: NCDs 3; Infections 2

“…They include themes on cancer, [13][14][15][16][17][18][19][20][21][22][23][24] diabetes mellitus, [25][26][27][28][29] respiratory and cardiovascular illnesses, [30][31][32][33][34][35] and others. [36][37][38][39][40][41][42] The non-communicable diseases theme is then followed by infectious diseases, ranging from HIV, [43][44][45][46][47][48][49] the COVID-19 pandemic, [50][51][52][53][54][55][56][57] and others. [58][59][60][61][62][63][64][65][66] We conclude the issue with a hybrid of papers [67][68]…”